Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae466 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Isabel Leroux-Roels und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccinology, Ghent University, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Clostridioides difficile, Bacterial Vaccines, Clostridium Infections, Immunogenicity, Vaccine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals, SA.
Abstract (Originalsprache)
Background
This study investigated the safety, reactogenicity, and immunogenicity in healthy subjects of a Clostridioides difficile vaccine candidate with/without adjuvant, targeting toxins A and B.
Methods
In this first-in-human, phase 1, observer-blind study, subjects aged 18–45 years were randomized to receive F2 antigen (n = 10) or placebo (n = 10), and subjects aged 50–70 years to receive F2 antigen plus AS01 adjuvant (n = 45), F2 antigen (n = 45), or placebo (n = 30) in 2 doses 1 month apart. A subcohort (n = 40) received a third dose 15 months later. Solicited adverse events (AEs) were recorded for 7 days and unsolicited AEs for 30 days after each dose. Immunogenicity was assessed at baseline and after each dose.
Results
Solicited AEs were transient and most frequent in subjects receiving F2 antigen plus AS01. No serious AEs were considered related to study vaccine. Immunogenicity was substantially higher in subjects receiving F2 antigen plus AS01 than subjects receiving F2 antigen alone. A third dose increased the immune response in subjects with baseline neutralization titers below the assay lower limit of quantitation.
Conclusions
The GSK C. difficile vaccine candidate was immunogenic, especially when given with AS01, and was well tolerated with an acceptable safety profile. Clinical Trial Registration NCT04026009.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vaccinology, Ghent University, Ghent University Hospital, Ghent, Belgium.
- GSK, Rixensart, Belgium.
- GSK, Amsterdam, The Netherlands.
- GSK, Wavre, Belgium.
Förderung
- GlaxoSmithKline Biologicals
- GlaxoSmithKline Biologicals, SA
Zitieren
APA
Leroux-Roels, I., Alhatemi, A., Caubet, M., De Boever, F., de Wergifosse, B., El Idrissi, M., Ferreira, G. S., Jacobs, B., Lambert, A., Morel, S., Servais, C., & Yarzabal, J. P. (2025). Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae466
Vancouver
Leroux-Roels I, Alhatemi A, Caubet M, De Boever F, de Wergifosse B, El Idrissi M, et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae466
BibTeX
@article{LerouxRoels2025,
author = {Leroux-Roels, Isabel and Alhatemi, Azhar and Caubet, Magalie and De Boever, Fien and de Wergifosse, Bertrand and El Idrissi, Mohamed and Ferreira, Guilherme S and Jacobs, Bart and Lambert, Axel and Morel, Sandra and Servais, Charlotte and Yarzabal, Juan Pablo},
title = {Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae466}
}
EUVIMED